SAAM II, short for "Simulation Analysis and Modeling" version 2.0, is a renowned computer program designed for scientific research in the field of bioscience.

SAAM II facilitates the construction and simulation of models, providing researchers with a friendly user interface allowing the quick run and multi-fitting of simple and complex (linear and nonlinear) structures and data.

Funded by NIH, popKinetics is specifically developed for population analysis of compartmental models built within SAAM II.

The results obtained from SAAM II have received indirect validation through extensive usage over many years, replication of modeling in other programs, and publication in peer-reviewed journals.

In general, there was good agreement (<1% difference) between SAAM II and WinNonlin in terms of parameter estimates and model predictions.

Peer-Reviewed Publications: Notably, the glucose-insulin Minimal Models that are used in clinical trials to quantify insulin improvements of antidiabetic treatments, are implemented in SAAM II.

Mones decided that compartmental models (systems of differential equations) were the best way to analyze the transient (kinetic) data being collected.

Through several grants, in the 2000-2012 period, Foster and Vicini worked on generating the modern version 2.1, including a population analysis add-on called popKinetics.

In 2012, the Epsilon Group, a Medical Automation Company in Virginia licensed the commercial rights to improve and distribute the software.

The leadership and management of SAAM II were assumed by Simone Perazzolo, a scientist with experience in computational modeling of biological and pharmacological systems.